2019 International Meeting on the Molecular Biology of Hepatitis B Viruses

2019乙型肝炎病毒分子生物学国际会议

• 批准号: 9762314
• 负责人: JOHN E TAVIS
• 金额: $ 0.7万
• 依托单位: HEPATITIS B FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2020-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9762314
• 关键词: Address; Affect; Animal Model; Animals; Anniversary; Antiviral Agents; Antiviral Therapy; Asia; Australia; Biochemistry; Biology; Biomedical Research; Cancer Etiology; Cell model; Cellular biology; Cessation of life; China; Chronic; Chronic Disease; Chronic Hepatitis B; Cirrhosis; Clinical; Communities; Development; Disadvantaged; Discipline; Disease; Drug Industry; Ensure; Financial Support; Foundations; Funding; Gene Expression; General Population; Genetic Transcription; Genotype; Grant; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Virus; Hepatitis Delta Virus; Human; Immunology; Indigenous; Individual; Industry; Innate Immune Response; International; Light; Liver Failure; Liver diseases; Malignant Neoplasms; Mission; Modeling; Molecular Biology; Molecular Virology; Morphogenesis; National Cancer Institute; National Institute of Allergy and Infectious Disease; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; Oral; Pathogenesis; Persons; Postdoctoral Fellow; Preventive vaccine; Primary carcinoma of the liver cells; Public Health; RNA Editing; Regulatory Element; Request for Proposals; Research; Research Personnel; Reverse Transcription; Scientist; Senior Scientist; Students; Time; Travel; Underrepresented Minority; United States; United States National Institutes of Health; Universities; Variant; Viral; Viral Pathogenesis; Virus; Virus Diseases; Virus Shedding; adaptive immune response; career; chronic infection; cost; gene therapy; graduate student; interest; lectures; low and middle-income countries; meetings; member; minority investigator; mortality; novel; novel strategies; novel therapeutic intervention; pathogen; posters; prevent; protein expression; symposium; therapy development; vector; virology; Address; Affect; Animal Model; Animals; Anniversary; Antiviral Agents; Antiviral Therapy; Asia; Australia; Biochemistry; Biology; Biomedical Research; Cancer Etiology; Cell model; Cellular biology; Cessation of life; China; Chronic; Chronic Disease; Chronic Hepatitis B; Cirrhosis; Clinical; Communities; Development; Disadvantaged; Discipline; Disease; Drug Industry; Ensure; Financial Support; Foundations; Funding; Gene Expression; General Population; Genetic Transcription; Genotype; Grant; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Virus; Hepatitis Delta Virus; Human; Immunology; Indigenous; Individual; Industry; Innate Immune Response; International; Light; Liver Failure; Liver diseases; Malignant Neoplasms; Mission; Modeling; Molecular Biology; Molecular Virology; Morphogenesis; National Cancer Institute; National Institute of Allergy and Infectious Disease; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; Oral; Pathogenesis; Persons; Postdoctoral Fellow; Preventive vaccine; Primary carcinoma of the liver cells; Public Health; RNA Editing; Regulatory Element; Request for Proposals; Research; Research Personnel; Reverse Transcription; Scientist; Senior Scientist; Students; Time; Travel; Underrepresented Minority; United States; United States National Institutes of Health; Universities; Variant; Viral; Viral Pathogenesis; Virus; Virus Diseases; Virus Shedding; adaptive immune response; career; chronic infection; cost; gene therapy; graduate student; interest; lectures; low and middle-income countries; meetings; member; minority investigator; mortality; novel; novel strategies; novel therapeutic intervention; pathogen; posters; prevent; protein expression; symposium; therapy development; vector; virology

ABSTRACT/SUMMARY Hepatitis B virus (HBV) is a major global public health threat with over 290 million people worldwide chronically infected and over 887,000 deaths per year. HBV causes almost 40% of all hepatocellular carcinoma cases, which is the 2nd leading cause of cancer-related mortality worldwide. The current prophylactic vaccine has no impact on established chronic infection and there is no cure. The annual International HBV Molecular Virology Meeting is the only forum that gathers the international community of researchers who study molecular biology and pathogenesis of HBV and the closely associated hepatitis delta virus (HDV). In 2019, this meeting will be held for the first time in Australia, in the Asia/Pacific region where chronic hepatitis B is highly endemic, with over 110 million people affected. Importantly, rates of chronic HBV are up to ten times higher in Indigenous Australians than non-Indigenous, for reasons that are unclear. We request funding to support travel expenses for young scientists to participate in the 2019 International Meeting on the Molecular Biology of Hepatitis B Viruses. The 2019 meeting will provide the forum for scientific exchange and dissemination of the latest research information, including discussions regarding new therapeutic strategies for potentially curing HBV and HDV infections. An estimated 500-600 delegates will attend the 2019 meeting, which will mark the 35th anniversary of this important gathering. The meeting will consist of 8 oral scientific sessions, 2 poster sessions, and a mini-symposium focused on hepatitis B cure that will be held following the main meeting. The scientific interactions will also be facilitated by 3 keynote addresses from experts outside the HBV field who will bring different perspectives. Importantly, at the 2019 International HBV meeting we will hold a public forum for the first time where leading scientists from the International HBV meeting can engage with members of the general public, media, students and members of the HBV affected community to discuss HBV, chronic disease, new treatments, and approaches to cure in lay terms. The Forum will be held at the conclusion of the main meeting to ensure it does not clash with presentations at the Scientific meeting. As in the past, great effort has been made to minimize the cost of the meeting, with a major strength of the meeting organization being continual support from the Hepatitis B Foundation since 2005, including publicizing the meeting to universities with large numbers of underrepresented minorities. In order to allow the participation of junior and minority investigators, support from the National Institutes of Health to help defray the costs of the 2019 meeting is requested. This funding will be used to ensure attendance and presentation by early career researchers, particularly from low and middle-income countries, as well as disadvantaged groups including Indigenous Australians.

摘要/摘要 乙型肝炎病毒（HBV）是全球主要的公共卫生威胁，全球超过2.9亿人 每年长期感染，超过887,000人死亡。 HBV导致所有肝细胞的40％ 癌病例，这是全球与癌症相关死亡率的第二大原因。电流 预防性疫苗对已建立的慢性感染没有影响，并且无法治愈。 年度国际HBV分子病毒学会议是唯一聚集的论坛 研究分子生物学和HBV和密切的分子发病机理的国际研究人员社会 相关的肝炎三角洲病毒（HDV）。 2019年，这次会议将首次在澳大利亚举行 慢性肝炎B高度流行的亚洲/太平洋地区，有超过1.1亿人受到影响。 重要的是，澳大利亚土著人的慢性HBV率是非土著人的十倍 不清楚的原因。 我们要求资金支持年轻科学家参加2019年的旅行费用 国际丙型肝炎病毒分子生物学会议。 2019年会议将提供 科学交流和传播最新研究信息的论坛，包括讨论 关于潜在治疗HBV和HDV感染的新治疗策略。估计500-600 代表将参加2019年会议，该会议将纪念这一重要聚会的35周年。 这次会议将包括8个口头科学会议，2个海报会议和一个小型群岛。 在丙型肝炎治疗上将在主要会议结束后举行。科学互动也将促进 通过HBV领域以外的专家的3个主题演讲，他们将带来不同的观点。重要的是，在 2019年国际HBV会议我们将首次举行公共论坛 国际HBV会议可以与公众，媒体，学生和成员互动 HBV受影响的社区讨论HBV，慢性病，新疗法以及治愈方法 外行术语。该论坛将在主要会议结束时举行，以确保其不会与 科学会议上的演讲。 与过去一样，已经付出了巨大的努力来最大程度地减少会议的成本，并以重大优势 自2005年以来，会议组织一直是丙型肝炎基金会的持续支持，包括 向大量代表性不足的少数群体的大学宣传会议。为了允许 大三和少数民族调查员的参与，美国国立卫生研究院的支持以帮助辩护 要求2019会议的费用。这笔资金将用于确保由 早期的职业研究人员，特别是来自低收入和中等收入国家以及处境不利的群体 包括澳大利亚土著人。